Our Biosimilars Pipeline
We are developing biosimilar compounds for the treatment of autoimmune diseases. We currently have one approved biosimilar.
| Compound | Clinical phase | Key Indications | Mode of action | More information |
|---|---|---|---|---|
| BI 695501 (adalimumab biosimilar candidate) |
approved | Rheumatoid arthritis, Psoriasis, Inflammatory Bowel Disease | Anti-Tumor Necrosis Factor-alpha (TNFa) | For more information click here |